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Summary. Cholesterol is a critical component of
biological membranes, which not only plays an essential
role in determining membrane physical properties, but
also in the regulation of multiple signaling pathways.
Cells satisfy their need for cholesterol either by uptake
from nutrients and lipoproteins or de novo synthesis
from acetyl-CoA. The latter process occurs in the
endoplasmic reticulum, where transcription factors that
regulate the expression of enzymes involved in the de
novo cholesterol synthesis reside. Cholesterol is
distributed to different membranes most prominently to
plasma membrane, where it participates in the physical
organization of specific membrane domains.
Mitochondria, however, are considered cholesterol-poor
organelles, and obtain their cholesterol load by the action
of specialized proteins involved in its delivery from
extramitochondrial sources and trafficking within
mitochondrial membranes. Although mitochondrial
cholesterol fulfills vital physiological functions, such as
the synthesis of bile acids in the liver or the formation of
steroid hormones in specialized tissues, recent evidence
indicates that the accumulation of cholesterol in
mitochondria may be a key step in disease progression,
including steatohepatitis, carcinogenesis or Alzheimer
disease. 
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Introduction
Cholesterol is an integral component of cell
membranes that plays an essential role in their integrity
and function. The name originates from the greek chole-
(bile) and stereos (solid), with the chemical suffix-ol
denoting an alcohol, as researchers first identified
cholesterol in solid form in gallstones in the XVIII
century. As an important membrane component in higher
eukaryotes, cholesterol helps to generate a
semipermeable barrier between cellular compartments
and to regulate membrane fluidity. Moreover, cholesterol
induces membrane packing in specific microdomains of
the plasma membrane, providing a platform for a variety
of membrane-associated signaling proteins. Due to this
role in modulating membrane structure and function
cholesterol levels are tightly regulated. The main sources
of cellular cholesterol involve its uptake from
cholesteol-rich low-density lipoproteins (LDL) or its de
novo synthesis from acetyl-CoA. Cholesterol and its
metabolites, such as steroids and bile acids, have
important biological roles as signal transducers and in
the solubilization of other lipids. Synthesized in the
endoplasmic reticulum (ER), cholesterol is then
distributed to different membranes, including
mitochondria, where it plays key physiological
functions. Although the role of cholesterol in
pathogenesis has been best recognized in cardiac and
brain vascular diseases, emerging evidence points to the
small pool of mitochondrial cholesterol as a key factor in
several disorders, including steatohepatitis,
carcinogenesis and neurodegeneration, such as
Alzheimer disease. The present review summarizes
current concepts on the cell biology of cholesterol, its
trafficking and functions in membrane structure, to then
focus on mitochondrial cholesterol and its role in cell
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death regulation and pathophysiology.
Cholesterol sources and regulation
There are two general mechamisms whereby cells
meet their needs for cholesterol, namely, its de novo
synthesis from acetyl-CoA and the more prominent route
as supplied from the diet (Grundy, 1983). Factors,
however, which regulate the endogenous synthetic rate,
absorption or the dietary cholesterol load can modulate
the relative balance between both pathways in the supply
of cholesterol.
The two faces of the mevalonate pathway 
Cells synthesize cholesterol de novo from acetyl
CoA through the mevalonate pathway (Fig. 1). The
enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG
CoA) reductase (HMGCoAR) catalyzes the reduction of
HMG CoA to mevalonate, the rate-limiting step in the
synthesis of cholesterol and nonsterol isoprenoids that
are indispensable for cell function (Goldstein and
Brown, 1990). Mevalonate is then phosphorylated to
pyrophosphomevalonate, which is then converted to
isopentenyl pyrophosphate (IPP). Isopentenyl
pyrophosphate can be reversibly transformed to
dimethylallyl pyrophosphate (DMAPP). IPP and
DMAPP combine to form the 10-carbon isoprenoid
geranyl pyrophosphate (GPP). Additional IPPs can be
added to produce farnesyl pyrophosphate (FPP), the 15-
carbon isoprenoid and geranylgeranyl pyrophosphate
(GGPP), the 20-carbon isoprenoid. Isoprenoids are lipid
moieties that are added to various proteins during post-
translational modification and anchor these proteins to
the cell membrane. In general, FPP prenylates proteins
in the Ras family, whereas GGPP prenylates those of the
Rho family (Edwards and Ericsson, 1999). Alternatively,
FPP can be converted into squalene by squalene
synthase (SS), which catalyzes the first step in the
committed pathway for cholesterol. Inhibition of this
pathway by statins prevents the formation of both
mevalonate and its downstream product, IPP, and this
inhibition can be reversed completely by mevalonate.
Supplementation with FPP or GGPP restores
farnesylation and geranylgeranylation of target proteins,
respectively. As one can infer from this pathway, the
therapeutic effects of statins can be cholesterol-
independent, which may reflect the modification of
protein isoprenylation, essential for their final function.
In contrast to this caveat with statins, the inhibition of
SS can result in selective cholesterol downregulation
without exerting major effects in the isoprenylation of
proteins (Brusselmans et al., 2007). Although SS
inhibition is not necessarily expected to result in the net
increase in farnesol, as it may be diverted to isoprenoid
synthesis via the farnesyltransferase, this potential pitfall
needs to be critically evaluated. Indeed, farnesol
accumulation due to farnesyltransferase inhibition has
been shown to induce cell death via ER stress or direct
transcriptional induction of CHOP in cancer cells (Joo et
al., 2007; Sun et al., 2007).
Feedback and transcriptional control of HMG CoAR.
HMG CoAR is embedded in the ER through an N-
terminal domain, with the catalytic domain projecting
into the cytosol (Gil et al., 1985). Sterol and nonsterol
endproducts of the mevalonate pathway control HMG
CoAR, to allow for continued production of essential
nonsterol isoprenoids, while minimizing the
overgeneration of cholesterol and potentially toxic
derivatives. One mechanism for feeback control involves
the rapid degradation of HMG CoAR, which is mediated
by ER residing proteins, Insig-1 and Insig-2.
Accumulation of sterols in ER membranes triggers
binding of the membrane domain of HMG CoAR to a
subset of Insigs, which carry a membrane-anchored
ubiquitin ligase called gp78, which begins the
ubiquitination of the reductase and marks the enzyme for
proteasomal degradation (Sever et al., 2003; Song et al.,
2005). 
Sterol regulatory element-binding proteins
(SREBPs), a family of ER membrane-bound
transcription factors which play an essential role in
lipogenesis, constitute another mechanism for feedback
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Fig. 1. The mevalonate pathway. The de novo synthesis of cholesterol
proceeds via mevalonate formation from acetyl-CoA. The generation of
farnesyl pyrophosphate branches out into the non-sterol arm comprising
isoprenoids, which can modify proteins post-translationally, and the
sterol arm in which the formation of farneyl pyrophosphate into squalene
is committed to cholesterol synthesis. Statins block very upstream in the
pathway, preventing mevalonate formation from HMG-COA, while the
inhibition of squalene synthase may be more specific to prevent
cholesterol synthesis without perturbing isoprenoid synthesis.
regulation of HMG CoAR. When the cellular supply of
sterols is low, SREBPs are transported from the ER to
the Golgi, where they are proteolytically processed by
specific proteases SP-1 and SP-2, resulting in the release
of soluble fragments to the cytosol. Processed matured
SREBPs forms then migrate to the nuclei to induce the
transcription of target genes (Fig. 2). SREBPs exhibit
differential specificity towards lipogenesis pathways.
While SREBP-1c transcriptionally stimulates the
synthesis of fatty acids, SREBP-2 is specifically
involved in the induction of genes responsible for
cholesterol synthesis, including HMG CoAR (Brown
and Goldstein, 1980; Horton et al., 2002; Browing and
Horton, 2004). Translocation of SREBP-2 from the ER
to Golgi requires the sterol-responsive escort protein
Scap (Rawson et al., 1999). Like HMG CoAR, Scap
contains a hydrophobic N-terminal domain that spans
the ER membranes and a C-terminal domain located in
the cytosol which mediates association with SREBPs
(Nohturfft et al., 1998). Cholesterol triggers binding of
Insigs to the membrane-spanning helices 2-6 of Scap,
which prevents the incorporation of Scap and its bound
SREBPs into COPII-coated vesicles, which function in
the transport from the ER to the Golgi (Yang et al., 2002;
Yabe et al., 2002; Ikonen, 2008). In this process
cholesterol directly binds to the membrane domain of
Scap, inducing a conformational change that triggers
Insig binding, thus blocking the exit of Scap-SREBP
from the ER. While the sterol nucleus and the 3ß
hydroxyl group of cholesterol are essential for Scap
recognition, the iso-octyl side chain is dispensable for
binding (Brown et al., 2002; Adams et al., 2004). Unlike
cholesterol, lanosterol, the first sterol intermediate in
cholesterol synthesis, neither binds Scap nor blocks the
proteolytic activation of SREBPs, but induces Insig-
dependent ubiquitination and degradation of HMG
CoAR (Song et al., 2005a). In addition, although
farsenoid X receptor is known to regulate multiple
metabolic processes (Wang et al., 2008), it also controls
cholesterol synthesis via induction of hepatic Insig-2
(Hubbert et al., 2007).
Finally, another level of regulation of cholesterol
synthesis is exerted by the availability of oxygen, as
cholesterol synthesis is an oxygen intensive process
needed in the biotransformation of squalene to
cholesterol. The bulk for the oxygen requirement centers
on the sequential removal of three methyl groups of
lanosterol (4α, 4ß, 14α), resulting in zymosterol. Indeed,
the yeast orthologs of mammalian SREBPs and Scap
called Sre1 and Scp1 function in a mechanism that uses
sterol synthesis as an indicator of oxygen availability
(Hughes et al., 2005). In addition, hypoxia has been
reported to inhibit cholesterol synthesis in rabbit skin
fibroblasts, although the efflux of cholesterol was also
suppressed (Mukodani et al., 1990). More recent
findings have reported that hypoxia stimulates
degradation of HMG CoAR through both accumulation
of lanosterol and HIF-1α-mediated Insigs induction
(Nguyen et al., 2007). 
Dietary cholesterol and transfer between tissues
In addition to the finely tuned pathway of cholesterol
synthesis, cells acquire cholesterol from the diet, with
the liver playing a key role (Getz and Reardon, 2006).
Cholesterol from the diet is first transported from the gut
to the liver, from where it is delivered to other tissues.
Enterocytes and hepatocytes package cholesterol and
cholesteryl esters into lipoproteins, which are further
modified in the circulation. Dietary cholesterol is
absorbed by enterocytes, which package it with
triglycerides to form chylomicrons. Limited triglycerides
hydrolysis occurs in the circulation and new apoproteins
(e.g. ApoE) are added to generate chylomicron remnants
that are taken up by hepatocytes. Hepatocytes, in turn,
secrete lipids in very low density lipoprotein (VLDL)
particles that are processed in the circulation into LDL,
which functions as the main vehicle to deliver
cholesterol to peripheral tissues. When extrahepatic
tissues have excess cholesterol, it can be released to
HDL, which can return the lipid load to the liver in a
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Fig. 2. Cholesterol synthesis at the ER and trafficking. Cholesterol is
synthesized de novo at the ER by a complex process involving the
proteolytic activation of transcription factor SREBP-2 by a ER-Golgi
cross talk. Immature SREBP-2 is accompanied by Scap to the Golgi,
where it is hydrolyzed at specific sites by Golgi-resident proteases SP-1
and SP-2 to yield the mature SREBP-2 form, which migrates to the
nuclei to induce transcription of targes genes, including HMG-CoAR.
Once synthesized in the ER, cholesterol is then distributed to other
sites, predominantly to the plasma membrane, and other minor
destinations, such as mitochondria by the action of StARD1. 
process called reverse cholesterol transport. From the
liver, cholesterol is secreted into the bile, either as
cholesterol or after it has been metabolized to bile acids
to enter then in the small intestine. Cholesterol and bile
salts from the intestine are either reabsorbed
(enterohepatic cycle) or excreted into faeces. Several
mechanisms exist for the uptake of cholesterol or its
shuttling between organelles, which contribute to the
regulation of the levels of membrane cholesterol to avoid
its accumulation, as it may have adverse effects in
membrane biophysics and function (see below).
Cholesterol trafficking and intracellular distribution
To ensure adequate levels within membranes,
cholesterol undergoes key processing steps in different
subcellular localizations, being transferred between
subcellular membranes either by membrane (or
vesicular) transport and by non-vesicular mechanisms
(Socio and Breslow, 2004; Maxfield and Tabas, 2005).
Membrane trafficking proceeds through vesicular and
tubular intermediates that transport membrane
components between subcellular organelles along the
cytoskeleton by specific carriers, some of which are
cholesterol-enriched (Maxfield and Tabas, 2005; Ikonen,
2006).
Non-vesicular cholesterol transfer occurs by the
action of cytosolic lipid transfer proteins. The paradigm
of this sort of mechanism is exemplified by CERT
(ceramide transfer protein), which facilitates
intercompartmental lipid transfer and which contains
domains for lipid binding and targeting to the donor and
acceptor membranes (Hanada et al., 2003). This type of
traffic is thought to be mediated by membrane contact
sites, and could also apply for sterols. CERT belongs to
the START protein family, other members of which bind
cholesterol (see below). Furthermore, oxysterol binding
proteins (OSBP) display affinity for cholesterol in
addition to oxysterols, and were shown to have a role in
the transport of ceramide from the ER to the Golgi,
which suggests a close connection between sterol and
sphingolipid regulation (Tsujishita and Hurley, 2000;
Perry and Ridway, 2006). The most striking evidence for
the role of lipid transfer proteins in intermembrane sterol
transport derives from S. cerevisiae that lack START
protein homologues, called Osh proteins. When these
Osh proteins are deleted, sterol delivery from the plasma
membrane to the ER is virtually suppressed
(RayChaudhuri et al., 2006), indicating that Osh proteins
performed overlapping functions in sterol transport. 
Once synthesized in the ER from acetyl-CoA
cholesterol leaves the ER very quickly, mostly by non-
vesicular mechanisms that bypass ER-Golgi membrane
transport, which accounts for the low ER sterol content
(Baumann et al., 2005). The biosynthetic sterols,
including cholesterol and a considerable fraction of its
precursors, such as zymosterol, lanosterol and
desmosterol, are rapidly targeted to the plasma
membrane and become available to extracellular
acceptors (Lange et al., 1991; Ikonen, 2006).
Alternatively, the newly synthesized cholesterol
equilibrates with the pre-existing cholesterol pool in
different sites, including endosomal compartments (Cruz
and Chang, 2000; Maxfield and Tabas, 2005). Although
the yeast Osh proteins have been proposed in an ER-
plasma membrane sterol transport, they may do so by
influencing the ability of the plasma membrane to
sequester sterols (Sullivan et al., 2006). An important
mechanism to reduce unesterified sterol levels in the ER
is esterification, which is catalyzed by acyl CoA
cholesterol acyltransferase (ACAT). Fatty acid sterol
esters are stored in lipid droplets, which have been
considered as passive fat deposits, although current
evidence points to these bodies as dynamic regulated
organelles (Martin and Parton, 2006). At least in
adipocytes, considerable amounts of unesterified
cholesterol are stored in lipid droplets (Prattes et al.,
2000). Cholesterol feeding to cells has been shown to
induce the trafficking of plasma membrane caveolin to
lipid droplets, where it played a key role in regulating
unesterified cholesterol levels (Le Lay et al., 2006). 
As mentioned above, and as an alternative
mechanism to de novo synthesis, cells acquire
cholesterol from extracellular lipoproteins, which are
taken up by receptor-mediated endocytosis. LDL
receptors are present in the plasma membrane of most
cells and exhibit affinity for particles that contain ApoB
or ApoE proteins, such as chylomicron remnants, VLDL
and LDL. These particles are endocytozed by clathrin-
coated vesicles and transported to acidic endocytic
compartments, where cholesteryl esters are hydrolyzed
by acid lipase in the lysosomes to provide unesterified
cholesterol. The endosomal membranes of
multivesicular late endosomes are enriched in the
phospholipid lysobisphosphatidic acid/ bismono-
acylglycerophosphate (LBPA/BMP) and function in the
regulation of cholesterol transport, possibly by
controlling the back fusion of internal vesicles with late
endosomes (Kobayashi et al., 1999). The multivesicular
late endosomes harbor two proteins, NPC1 and NPC2,
which play a crucial role in cholesterol trafficking out of
the endosomal system. Indeed, deficiency of either of
these proteins leads to the accumulation of LDL-derived
unesterified cholesterol in late endocytic organelles
(Sturley et al., 2004). Although both proteins can bind
sterols, they also have been implicated in sphingolipid
binding (Ohgami et al., 2004; Sleat et al., 2004; Sturley
et al., 2004). Evidence from mice deficient in NPC1 and
NPC2 indicates that these proteins cannot compensante
for each other (Sleat et al., 2004). While NPC1 is a large
glycoprotein comprised of 13 membrane-spanning
domains, NPC2 is a small soluble protein that functions
as a cholesterol transfer protein in vitro. Although NPC1
deficiency results in major neurodegenerative sequelae,
it also affects the pancreas and the liver, resulting in
marked cholesterol accumulation (Fig. 3), which
contributes to the hepatic deterioration which, in some
cases, leads to premature death even before the onset of
the neurological symptons.
Another site in the endocytic pathway for active
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sterol exchange is the recycling compartment. Recycling
endosomes are enriched in sterol- and sphingolipid and
function as acceptors for non-vesicular sterol flux
through the cytosol (Gagescu et al., 2000). Vesicular
trafficking is regulated by several Rabs proteins, such as
Rab7, Rab9 and Rab11. Once released from the
endolysosomal system, cholesterol is delivered to other
membranes, such as the plasma membrane, ER,
recycling endosomes and mitochondria. 
Role of cholesterol on membrane properties
Cholesterol and membrane domains
The classical fluid mosaic model proposed by Singer
and Nicholson envisaged biological membranes as a
phospholipid bilayer matrix, within which lipids and
proteins are homogeneously mixed and free to move
(Singer and Nicholson, 1972). In the last decades,
evidence has accumulated for a considerably more
heterogeneous picture of membrane organization,
leading to the current notion where lipids and proteins
can be temporarily confined to distinct regions of the
membrane (i.e. membrane domains) (Vereb et al., 2003).
Although many questions remain unanswered, a large
body of data supports the view of cholesterol playing a
key role in biomembrane compartimentalization.
Cholesterol-based lateral lipid segregation
An important contribution to our present view of
biomembrane structure is the observation, in
phospholipid mixtures containing high fractions of
cholesterol, of the coexistence of two liquid lipid phases
delimited by a phase boundary, a phenomenon not
observed in phospholipids bilayers in the absence of
cholesterol (Fig. 4) (Feyngenson, 2007). These two
phases, termed the liquid-disordered (Ld) and liquid-
ordered (Lo) phase, are distinguished by a different
average conformational lipid chain order. Specifically,
phospholipids in the Ld phase enjoy more freedom in
acyl chain motions than phospholipids in Lo phase,
while, at the same time, lipid molecules in both phases
keep similarly fast in-plane rotational and translational
mobility. What is the basis for the cholesterol-driven
lateral segregation of phospholipids into Lo and Ld
phases? In contrast to in vivo studies, model membrane
systems have provided an excellent opportunity to
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Fig. 3. NPC1 deficiency results in
cholesterol accumulation. The
endosomal protein NPC1 plays a key
role in cholesterol traff icking to
different destinations within the cell. Its
deficiency causes cholesterol
accumulation in cells, which is thought
to contribute to the neuronal and
hepatic deterioration of individuals
affected by NPC1 disease. The bottom
images illustrate the accumulatin of
free cholesterol by filipin staining in
hepatocytes from NPC1 knockout
mice compared to wild type cells.
investigate this issue in detail. The behaviour of Lo and
Ld lipid phases has been systematically examined for
more than three decades by a large number of
biophysical techniques (e.g. X-ray diffraction,
calorimetry, fluorescence microscopy), to even yield
complete phase diagrams (Feyngenson, 2007; Veatch,
2007). Coexisting Lo and Ld phases have been routinely
observed in three-component mixtures containing
cholesterol, and at least two types of phospholipids, one
with saturated hydrocarbon chains and a high chain-
melting temperature, such as sphingomyelin (SM), and
another with at least one unsaturared hydrocarbon chain
and low chain-melting temperature, as found in many
naturally-occurring phosphoglycerides. A consensus
emerged in that the adopted phase depends on
phospholipid structure: those containing saturated chains
tend to segregate into cholesterol-enriched Lo phases;
whereas those containing unsaturated chains tend to be
enriched in cholesterol-poor Ld phases. Considering the
rigidity conferred to cholesterol by its four fused-ring
structure and the lower flexibility of saturated acyl
chains relative to unsaturated ones, it follows that the
packing of cholesterol with saturated lipids is
entropically more favorable than with unsaturated lipids
(McConnel and Vrljic, 2003; Almeida et al., 2005). In
addition to van der Waals and hydrophobic interactions
between phospholipid acyl-chains and the steroid moiety
of cholesterol, hydrogen-bonding and charge-pairing
interactions between lipid headgroups may also
contribute to Lo/Ld lipid phase separation.
Cholesterol-rich lipid rafts
The property of ternary mixtures of cholesterol and
saturated/unsaturated phospholipids to separate into Lo
and Ld phases is thought to be at the origin of lipid rafts,
a type of membrane domain that has drawn the attention
of researchers during the last decade (Rietveld and
Simons, 1998). According to the raft hypothesis, tight
packing of cholesterol with saturated phospholipids (in
particular, sphingolipids) is required and sufficient to
generate “rafts” of Lo lipids floating in a “sea” of
unsaturated Ld phospholipids in biological membranes.
This has led to the notion that lipid-lipid forces direct
cellular membrane compartimentalization, the proteins
being sorted depending on their affinity for lipid raft
domains. Cholesterol-enriched rafts have been proposed
to play active roles in a wide range of physiological
processes, including signal transduction, protein sorting,
cellular entry of viruses/toxins and apoptosis (Simons
and Vaz, 2005). At a more fundamental level, such
membrane domains would serve to enhance or diminish
particular protein-protein interactions, while maintaining
classical protein-protein specificities. 
However, in contrast to the broad consensus and
clear evidence for cholesterol-dependent lateral lipid
segregation in model membranes, the nature and even
existence of cholesterol-rich rafts in living cells are
currently under debate (Jacobson et al., 2007). This is in
part due to the difficulties to isolate, detect and
characterize these structures in vivo. The existence of
rafts was initially inferred from biochemical studies that
consistently found a “detergent-resistant membrane
fraction” rich in cholesterol and (glyco)sphingolipids, as
well as specific proteins (Simons and Vatz, 2005). Since
then, the implicit assumption has often been made that
detergent-resistant fractions obtained from cellular
extracts provide valuable information about the
characteristics of rafts domains and that they resemble
their native environment. This test has come into
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Fig. 4. Role of cholesterol in
membrane properties. A: Cholesterol-
induced lipid phase separation.Top:
Schematic drawing of
phosphatidylcholine (PC),
sphingomyeline (SM). and cholesterol
(CHOL) molecules. Middle: Typical
organization found in PC/SM mixtures
(liquid disordered (Ld) phase) Bottom:
Typical organization found in
PC/SM/CHOL, with SM/CHOL
segregating in a liquid-ordered (Lo)
phase. B. Cholesterol and bilayer
elasticity.Top: Different effective
shapes and intrinsic curvatures of
representative lipids. LPC:
lysophosphatidylcholine. Bottom:
Bending of bilayer leaflets into a lipidic
pore. Note that CHOL should be
excluded from the pore lining thereby
opposing lipidic pore formation..
question because there is a range of detergent-insoluble
structures that can be isolated from cell membranes,
depending on experimental conditions, and due to the
possibility that detergent treatment might artificially
relocate membrane constituents (Lichtengerb et al.,
2005). An additional difficulty is that while micron-sized
domains are readily visualized in cholesterol-containing
model membranes, existing methods do not provide
sufficiently high spatial and temporal resolution to
directly visualize raft domains in living cells.
Considering that lipid-lipid interactions can be
dramatically affected by the activity of enzymes that
generate phase-changing products (lipases, kinases) as
well as by cross-linking of proteins, it may not be
surprising that, unlike the outcome found in simple lipid
mixtures, raft domains only exist as transient
nanodomains under many conditions in living cells.
Another important difference between native biological
and pure lipid bilayer membranes is the presence of
membrane proteins. Thus, it is increasingly recognized
that in addition to lipids, proteins also play a crucial role
in biomembrane compartimentalization (Jacobson et al.,
2007).
Notwithstanding these caveats, it is indisputable that
many cell-types contain caveolae: well discernable flask-
shaped membrane domains enriched in caveolin protein,
cholesterol and sphingolipids (Parton and Simons,
2007). Moreover, new data emerged from the literature
supporting the relevance of cholesterol-dependent
phospholipid segregation, as characterized in model
membranes, for biomembrane compartimentalization.
Cholesterol and membrane elasticity
Biophysical studies with model membranes showed
that, even without actually inducing lateral lipid phase
separation, cholesterol has a major impact on membrane
elasticity (Fig. 4). In short, cholesterol (a) increases the
area compressibility modulus (ka), which is related to the
work required to laterally expand the bilayer surface
(Needham and Nunn, 1990); (b) augments the bending
modulus (kb), which reflects the work needed to bend
the bilayer (Meleard et al., 1997); and (c) imposes
negative intrinsic curvature (Co) in the bilayer (Chen and
Rand, 1997), which is a measure of the spontaneous
tendency of the lipid molecules to form curved surfaces
(Basañez, 2002). The restricted acyl chain motions
induced by cholesterol leading to tight intermolecular
interactions and augmentation of bilayer hydrophobic
thickness have been linked, respectively, to the low
lateral compressibility and high bending rigidity
observed in cholesterol-rich phospholipid bilayers
(Allende et al., 2004). On the other hand, the negative Co
of cholesterol correlates with the lower effective cross-
sectional area of its polar head group relative to that of
the acyl chains. All of these data, together with recent
theoretical calculations, indicates that cholesterol-rich
bilayers are more resitant to elastic deformations than
cholesterol-poor bilayers. 
The energetic cost associated with elastic
deformations of lipid bilayers has been related to a
variety of membrane-associated processes, including
membrane protein conformational changes (discussed
below) and formation of lipid-containing pores.
Regarding the latter process, the underlying concept is
that phospholipids can be organized in such a manner as
to form a hydrophilic pore. However, this process
requires significant deformation of constituent
membrane monolayers and so depends on bilayer elastic
properties. Specifically, lipidic pore formation should be
promoted by a decrease in Ka and/or Kb, as well as by
positive Co. Therefore, cholesterol and other lipids with
similar elastic properties should inhibit lipidic pore
formation. Data supporting this notion has been obtained
not only in studies with pure lipid bilayers, but also in
bilayers containing membrane-active antimicrobial
peptides (Basañez et al., 2002a). Lipidic pore formation
has also been implicated in BAX-driven mitochondrial
outer membrane permeabilization (MOMP, see below).
In fact, using in vitro reconstituted systems we obtained
strong experimental evidence that correlate BAX
permeabilizing function with formation of large
proteolipidic pores having net positive curvature
(Basañez et al., 2002a,b). These findings, together with
the observation that cholesterol inhibits the
permeabilizing activity of a pre-activated form of BAX
(Montero et al., 2008), supports the notion that
cholesterol inhibits BAX-driven membrane
permeabilization, at least in part, by increasing the
energetic cost associated with deforming membrane
monolayers into a highly bent proteolipidic pore.
Mitochondrial cholesterol: physiology and transport
Mitochondria are cholesterol-poor organelles with
estimates ranging from 0.5-3% of the content found in
other cellular membranes (Van Meer et al., 2008). This
controlled availability of cholesterol in mitochondrial
membranes plays important physiological roles in
specific tissues where cholesterol is used for
steroidogenesis and synthesis of steroid hormones
(Soccio and Breslow, 2004). This process involves the
initial transport of cholesterol to the inner mitochondrial
membrane before it is metabolized by P450scc
(CYP11A1), the rate-limiting step in steroidogenesis.
Mitochondrial sterol 27-hydroxylase (CYP27A1) is
widely distributed in numerous tissues and plays a
critical role in the regulation of cholesterol homeostasis.
In non-hepatic (peripheral) tissues, the 27-hydroxylation
of cholesterol by CYP27A1 has been proposed to
participate in the reverse cholesterol transport to the
liver. Within the liver, CYP27A1 initiates an alternative
pathway of bile acid biosynthesis, the so-called acidic
pathway (Stravitz et al., 1996; Hall et al., 2005). Both in
vivo and in vitro studies have shown that this acidic
pathway may be responsible for close to 50% of bile
acid synthesis. In contrast to these physiological roles,
the overenrichment of cholesterol in mitochondria can
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result in mitochondrial dysfunction and impairment of
specific carriers, including the mitochondrial transport of
GSH through alterations in mitochondrial membrane
order (Colell et al., 2003; Lluis et al., 2003; Fernandez-
Checa and Kaplowitz, 2005). Moreover, previous
findings have described the accumulation of cholesterol
in mitochondria in neurodegeneration or myocardial
ischemia injury (Rouslin et al., 1982;Yu et al., 2005). 
Despite the physiological role of cholesterol in
mitochondria, the mechanisms involved in the
trafficking to this compartment are poorly understood,
with StAR proteins playing a relevant role. Indeed, the
best characterization for a role of StAR family in the
mitochondrial delivery of cholesterol has been reported
in steroidogenic cells with the description and cloning of
several StARD subfamilies (Socio and Breslow, 2003).
MLN64/StARD3 is widely expressed and its
transmembrane domain localizes to late endosomes with
the StART domain facing the cytosol. While full-length
MLN64 is relatively inactive in steroidogenic assays, its
proteolysis could release the StART domain, allowing
delivery of cholesterol to mitochondria. However,
targeted mutation of the MLN64 StART domain has
been shown to cause only modest alterations in cellular
sterol metabolism. Mice homozygous for the Mln64
mutant allele exhibited minor alterations in the
metabolism and in the intracellular distribution of
cholesterol, questioning its contribution in the
intramitochondrial trafficking of cholesterol (Kishida et
al., 2004). StARD4 and 5 are structurally related to
StAR/StARD1, although they lack signal sequences to
target them to specific subcellular organelles. Mouse
StARD4 but not D5 is regulated by SREBPs, and both
exert low levels of StAR-like activity in COS-1 cells co-
transfected with the cholesterol side-chain cleavage
enzyme system (Miller, 2007). Thus the current view is
that the family of proteins related to StARD4 is
primarily responsible for delivering cholesterol to the
mitochondrial outer membrane (MOM) from elsewhere
in the cell (endoplasmic reticulum, lipid droplets). In
contrast, StAR/StarD1 has been shown to play a major
role in the intramitochondrial movement of cholesterol
from the mitochondrial outer membrane (MOM) to the
inner mitochondrial membrane (IMM) (Soccio and
Breslow 2003; Miller, 2007). Although this role has
been best described in steroidogenic tissues, StAR
mRNA and protein have been detected in primary
human hepatocytes and HepG2 cells (Hall et al., 2005).
Furthermore, StAR overexpression in rat hepatocytes
increased bile acid synthesis, whereas that of MLN64 or
the sterol carrier protein-2 (SCP-2) resulted in a modest
increase in this process (Pandak et al., 2002; Ren et al.,
2004). Thus, although StarD3, D4 and D5 may play a
minor role in the intramitochondrial trafficking of
cholesterol, they may participate in the delivery of
cholesterol to mitochondria. 
In addition to StAR-related lipid transfer proteins
(StART) in mitochondrial cholesterol trafficking, the
role for caveolin-1 in this process has been less
recognized. Studies on the function of caveolin-1
identified two main areas of relevance. Caveolin-1 has
been shown to function as a scaffolding protein involved
in organizing the activity of multiple signaling
molecules in caveolae (Okamoto et al., 1998). In
addition, caveolin-1 exhibits binding properties towards
fatty acids and cholesterol, which raise the possibility
that caveolin-1 mediates the intracellular transport of
lipids, such as cholesterol (Murata et al., 1995; Smith,
1996). Consistent with its scaffolding function, caveolin-
1 has been localized in caveolae in many cell types,
although this is not a universal location. Using
immunoelectron microscopy analysis, caveolin-1 has
been located in mitochondria from a variety of epithelial
cells, including hepatocytes (Li et al., 2001). Thus, it is
conceivable that in addition to its classical role in
membrane organization and signalling, caveolin-1 may
regulate the mitochondrial traffic of cholesterol.
Interestingly, caveolin-1 expression is altered in NPC1
mice with higher levels in heterozygous than in
homozygous mice (Garver et al., 1997), and NPC1
knockout mice have been shown to exhibit increased
cholesterol levels (Beltroy et al., 2005; Mari et al., 2006)
(Fig. 3), which suggests an inverse correlation between
mitochondrial cholesterol and caveolin-1. Currently, the
role of caveolin-1 in the regulation of mitochondrial
cholesterol and its impact on mitochondrial function and
energetics is under investigation.
Mitochondrial membrane domains
It is well established that healthy mitochondria
contain lower levels of cholesterol and sphingomyelin
compared with those found in the plasma membrane
(Daum and Vance, 1997). However, it is also
increasingly recognized that the content of particular
glycosphingolipids and cholesterol can increase in
mitochondrial membranes in response to certain stimuli
and metabolic alterations. For example, the
glycosphingolipids GD3/GM3 have been found to move
out from the plasma membrane and into mitochondria in
response to activation of cell-death receptors (Garcia-
Ruiz et al., 2002, 2003; Malorni et al., 2007; Morales et
al., 2007). We recently demonstrated that mitochondria
isolated from different hepatic cancer cells present
elevated levels of cholesterol and correlated this
phenomenon with cellular resistance to apoptotic death
(Montero et al., 2008). BAX-induced MOMP constitutes
a crucial step in most apoptotic pathways (Green and
Kroemer, 2004). Based on biochemical methods and
fluorescence microscopy analysis, Garofalo et al.
concluded that BAX and other pro-apoptotic proteins are
recruited to GD3-enriched mitochondrial membrane
domains, hijacking cells towards an apoptotic prone
phenotype (Garofalo et al., 2005). Interestingly, our
group and others found an inverse correlation between
mitochondrial cholesterol level and BAX-driven MOMP
(Lucken-Ardjomande et al., 2008; Montero et al., 2008).
Based on these data, it is tempting to speculate that,
under certain conditions, specific domains may be
formed at MOM, which in turn affect key reactions
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controlling cell death susceptibility.
Somehow related to the above phenomena, a
different type of mitochondrial domain is the so-called
mitochondrial membrane contact sites (CS).
Mitochondrial CS have been known for more than 30
years, being defined as morphologically discernable
mitochondrial regions where the outer and inner
membranes come into close proximity (Reichert and
Neupert, 2002). Ardail et al. identified two populations
of mitochondrial membrane CS in mammalian cells:
outer membrane CS and inner membrane CS (Ardail et
al., 1990). Interestingly outer/inner membrane CS
display notable differences in lipid composition and acyl
chain order. Specifically, relative to inner membrane CS,
outer membrane CS shows higher cholesterol to
phospholipid ratio, higher acyl chain saturation, and
reduced lipid chain order. Other studies demonstrated
that exogenous cholesterol that was translocated to the
inner membrane was also preferentially localized to
outer membrane CS, suggesting that CS are involved in
channelling cholesterol into mitochondria (Daum and
Vance, 1997). In line with this hypothesis, two proteins
implicated in mitochondrial cholesterol import, the
peripheral benzodiazepine-receptor (PBR) and StAR-D1
are also found enriched at mitochondrial CS (Daum and
Vance, 1997; Epand, 2006). Although there is little
doubt that proteins catalyze mitochondrial cholesterol
import, it is conceivable that the specific “raft-like” lipid
composition of mitochondrial CS also plays a role in this
process. 
Effect of cholesterol on mitochondrial membrane
proteins
Cholesterol may affect membrane protein function
via two fundamentally different types of interactions. On
the one hand, individual cholesterol molecules may
specifically recognize certain sites on membrane
proteins, which approximates to a classical “ligand-
receptor” interaction. On the other hand, cholesterol may
influence functional activities of membrane proteins by
altering collective properties of the lipid matrix,
considering bilayers as a homogeneous entity with
defined physical properties. Although many cases of
cholesterol regulated protein activities are known, we
focus here on two selected examples of cholesterol
action on membrane protein function of particular
interest in mitochondrial research. 
Cholesterol and the CRAC motif
A number of protein domains that recognize
cholesterol have been identified. One is the CRAC
motif, which stands for Cholesterol Recognition/
interaction Amino acid Consensus (Epand, 2006). This
motif is generally present as a short juxtamembrane
segment displaying the pattern -L/V-(X)(1-5)-Y-(X)(1-
5)-R/K-, in which (X)(1-5) represents between one and
five residues of any amino acid. The CRAC motif was
identified in the PBR, which is implicated in cholesterol
import into mitochondria (Li and Papadopoulos, 1998).
The CRAC motif has also been found in StARD1,
another protein implicated in intramitochondrial
transport of cholesterol described above (Epand, 2006). 
The structural basis of the specific interaction
between cholesterol and the CRAC motif has yet to be
firmly established. However, computer modelling
studies indicate that the hydroxyl group of cholesterol is
involved as an H-donor in complexing with the C=O of
the carboxyl-terminal R/K residue of the CRAC motif
(Epand et al., 2006). In the case of PBR, the central Y
residue of the CRAC motif has an additional role in
stabilizing interactions with cholesterol (Jamin et al.,
2005). Interestingly, there is evidence that both PBR and
StARD1 localize to mitochondrial outer membrane CS
(Daum and Vance, 1997), raising the possibility that
these two proteins act in a concerted fashion promoting
import of cholesterol into mitochondria.
Cholesterol and BAX
As mentioned before, BAX is another mitochondrial
protein localized to the MOM, whose function is
regulated by the mitochondrial cholesterol content.
However, unlike the case of PBR and StARD1, BAX
does not possess any sequence/structure known to
provide specificity for recognition of cholesterol. Rather,
two independent studies indicated that cholesterol affects
BAX function via bilayer-mediated (non-specific) effect
(Lucken-Ardjomande et al., 2008; Montero et al., 2008). 
In healthy cells, BAX exists as an inactive monomer
in the cytosol. BAX translocation to the outer
mitochondrial membrane followed by its
intramembranous oligomeric folding is considered an
early event during apoptosis. There is a lot of evidence
which links this change in BAX conformation to MOMP
induction. Interestingly, cholesterol accumulation
impairs membrane insertion and oligomerization of
BAX (Lucken-Ardjomande et al., 2008; Montero et al.,
2008). Moreover, a correlation exists between inhibition
of BAX conformational change and increased lipid acyl-
chain order. One explanation for these observations is
that cholesterol-mediated alterations in lateral lipid
organization (see above) inhibit BAX conformational
change. An alternative possibility is that cholesterol-
induced reduction of bilayer elastic deformability
inhibits not only BAX-induced lipidic pore formation
(see above), but also BAX conformational change. This
is in line with accumulating evidence indicating that
elastic bilayer deformation is an important factor
governing conformational transitions of membrane-
associated proteins (Janmey and Kinnunen, 2006;
Andersen and Koeppe, 2007).
Mitochondrial cholesterol in disease
Role in steatohepatitis
Steatohepatitis (SH) represents an advanced stage in
the spectrum of fatty liver diseases that encompasses
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alcoholic (ASH) and non-alcoholic steatohepatitis
(NASH), two of the most common forms of liver disease
worlwide. Although the primary etiology of ASH and
NASH is different, these two diseases show almost
identical histology features characterized by steatosis,
mixed lobular inflammation with scattered leukocytes
and mononuclear cells, and hepatocellular cell death due
to sensitivity to oxidative stress (Angulo, 2002). Despite
significant progress in recent years, the pathogenesis of
SH is still incompletely understood, although the two-
hits hypothesis is the most prevalent view to explain the
progression from steatosis to SH. In this hypothesis, the
accumulation of fat within hepatocytes constitues the
first hit, which somehow sensitizes the liver to an
upcoming stress, (e,g, oxidative stress, inflammation)
with inflammatory cytokines TNF/Fas playing a key role
in the disease (Tomita et al., 2006). Testing the
hypothesis that the type rather than the amount of fat in
hepatocytes is a crucial determinant of the susceptiblity
to TNF/Fas and using nutritional and genetic models of
hepatic steatosis, we observed that cholesterol
accumulation in hepatocytes, as opposed to triglycerides
or free fatty acids sensitizes to TNF/Fas-mediated SH
(Mari et al., 2006). Cholesterol accumulation in the ER
or the plasma membrane did not cause ER stress or alter
TNF signaling. Rather, we observed that the trafficking
of cholesterol to mitochondria accounted for the
hepatocellular susceptibility to TNF due to
mitochondrial GSH (mGSH) depletion. In addition,
hepatocytes from NPC1 knockout mice exhibit
accumulation of cholesterol into mitochondria resulting
in mGSH depletion and susceptibility to TNF (Mari et
al., 2006). Boosting the pool of mGSH or preventing its
depletion by blocking cholesterol synthesis with
atorvastatin, the susceptibility of obese ob/ob mice to
LPS-mediated liver injury was blunted, highlighting the
relevance of mitochondrial-mediated oxidative stress in
the susceptibility to TNF-induced liver injury and
NASH. 
Paralleling these findings with nutritional or genetic
models of NASH, alcohol-induced liver injury is
characterized by the susceptibility to TNF-mediated cell
death (Colell et al., 1998; Pastorino and Hoek, 2000;
Minagawa et al., 2004). Although the mechansims for
this transition from resistance to susceptibility to TNF
upon alcohol intake may be multifactorial (Shulga et al.,
2005), we observed that alcohol feeding causes mGSH
depletion due to alcohol-stimulated cholesterol synthesis
(Lluis et al., 2003; Fernandez-Checa and Kaplowitz,
2005). Cholesterol accumulation in mitochondrial
membranes impairs the mitochondrial transport of GSH
from the cytosol, resulting in its depletion (Colell et al.,
1997; Coll et al., 2003; Zhao et al., 2002). Similar
findings in the liver have been observed in the
intragastric model of alcohol administration in mice
(Nakagami et al., 2001) and in alveolar type-II cells
(Velasquez et al., 2002). mGSH has been associated with
increased susceptibility to ethanol-induced liver injury
and lethality in mice deficient in Nrf2, a transcription
factor that regulates GSH biosynthesis and homeostasis
(Lamlé et al., 2008). In order to unambiguously test
whether mGSH determines the hepatocellular
suscepbility to TNF/Fas, we have selectively depleted
mGSH with 3-hydroxy-4-pentenoate without effect on
the cytosol pool of GSH by exploiting its predominant
biotranformation in mitochondria (Mari et al., 2008). In
this paradigm, we have observed that mGSH depletion
sensitizes to TNF/Fas by enhancing the mitochondrial
generation of reactive oxgen species via acidic
sphingomyelinase-induced ceramide generation, causing
the peroxidation of cardiolipin, which facilitates the
permeabilizing activity of oligomerized BAX in the
MOM. In summary, cholesterol, particularly
mitochondrial cholesterol, emerges as a key factor that
contributes to the progression from steatosis to SH by
sensitizing hepatocytes to TNF/Fas via mGSH depletion.
Recent findings have confirmed the critical role of
cholesterol in SH (Matzusawa et al., 2007; Zheng et al.,
2008), strongly suggesting that therapy aimed at
lowering cholesterol synthesis and/or expand the
mitochondrial GSH defense may be of relevance in SH.
Role in (hepato)carcinogenesis
One of the striking features of tumorigenesis is the
deregulation of cholesterol metabolism (Siperstein,
1995). This is exemplified by the desensitization of
HMG-CoAR to inhibition by sterols, and by the
continued cholesterol synthesis in growing solid tumors.
As indicated above, cholesterol synthesis is oxygen
dependent (Nguyen et al., 2007), and hypoxia is a
prominent feature of solid tumor development and
considered a major driving force for tumor progression,
invasiveness and survival (Pennachietti et al., 2003;
Lluis et al., 2007). In addition, increased cholesterol
levels in mitochondria have been observed in in
heterotopic Morris hepatoma xenografts in Buffalo rats,
compared to the content found in mitochondria from
host liver (Feo et al., 1975; Crain et al., 1983). Since
cholesterol enrichment can adversely affect
mitochondrial functions (Colell et al., 2003; Yu et al.,
2005), it is conceivable that the accumulation of
cholesterol within mitochondrial membranes may
actually account or contribute to the known
mitochondrial dysfunction of cancer cells, underlying
the Warburg effect and dependence on glucolysis
(Giaccia et al., 2003). Indeed, using human and rat
hepatocellular carcinoma cell lines we have observed a
dramatic increase in the levels of mitochondrial
cholesterol compared to untransformed cells, which
translated in increased membrane order parameter
(Montero et al., 2008). This outcome was accompanied
by increased resistance to quemotherapy selectively
acting via mitochondria, which was reversed either by
cholesterol extraction or fluidization of mitochondrial
membranes. Moreover, giving the role of StAR in
regulation of mitochondrial cholesterol homeostasis (see
above), the downregulation of StAR in hepatocellular
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carcinoma cell lines by siRNA reduced the net levels of
mitochondrial cholesterol, increasing their susceptibility
to mitochondria-targeted chemotherapy. In line with
these data, Lucken-Ardjomande have recently shown
that treatment of HeLa cells with U18666A, which
caused mitochondrial cholesterol upregulation, showed a
delay in the release of Smac/Diablo and cytochrome c,
as well as in BAX oligomerization and partial protection
against stress-induced apoptosis (Lucken-Ardjomande et
al., 2008). Moreover, the inhibitory effect of cholesterol
on mitochondrial BAX activation was demonstrated in
liposomes, and this effect was exerted by a dual
mechanism involving changes in membrane order
parameter and in the decrease of BAX penetration into
the membrane (Montero et al., 2008). Thus, by strongly
inhibiting BAX-driven MOMP, cholesterol modulates
cell death susceptibility. Furthermore, the potentiation of
hepatocellular carcinoma chemotherapy by squalene
synthase inhibition by YM-53601 (Fig. 1), which
reduces cholesterol levels including in mitochondria
(Montero et al., 2008), without perturbing isoprenoid
metabolism, validates the specificity of cholesterol in
chemotherapy resistance, and revitalizes the potential
benefit of cholesterol downregulation in cancer 
therapy.
Role in Alzheimer disease
Alzheimer's disease (AD) is a major neuro-
degenerative disease whose incidence increases with
age. Unfortunately, our understanding of this disease is
far from complete, which not only reflects its
extraordinary complexity, but also limits the prospects
for treatment and manegement of this devastating
disease. The current available medicines for the
treatment of AD include acetylcholinesterase inhibitors
and the N-methyl-d-aspartate antagonist memantine, but
unfortunately their benefits are very modest and
ultimately do not prevent disease progression (Vardy et
al., 2006). AD is characterised by the deposition in the
brain of senile plaques, consisting predominantly of the
amyloid ß (Aß) peptide of 40-42 amino acids (Taylor et
al., 2002). Accumulation of Aß, particularly the longer
Aß1-42, initiates a cascade of events resulting in the
neurodegeneration seen in AD.
Aß is generated by proteolytic cleavage of the
membrane bound amyloid precursor protein (APP). In
the amyloidogenic pathway, the ß- and γ-secretases
cleave APP at the N- and C-termini of the Aß peptide,
respectively. ß-Secretase has been characterized as a
membrane-bound aspartic protease termed BACE1,
while γ-secretase is a complex comprised of presenilin-1
or -2, nicastrin, Aph-1 and Pen-2 (Haass, 2004).
Inhibition of the ß- and γ-secretases is considered a
viable therapeutic approach for AD treatment and
compounds that inhibit one or other protease are
currently under clinical trials (Vardy et al., 2006). In
addition to its amyloidogenic processing by ß- and γ-
secretases, APP can be cleaved within the Aß domain by
α-secretase. This non-amyloidogenic processing
prevents the deposition of intact Aß peptide and results
in the release of a large soluble ectodomain, sAPPα,
from the cell, which has neuroprotective and memory-
enhancing effects. Members of the ADAMs, a
disintegrin and metalloprotease family of proteases, have
been shown to possess α-secretase activity (Hooper and
Turner, 2002).
Although the functional relationship between
cholesterol and AD was suggested about 12 years ago,
epidemiological evidence established a link between
plasma cholesterol levels and AD development. High
cholesterol levels correlated strongly with Aß deposition
and the risk of developing AD, while conversely,
patients taking the cholesterol-lowering statin drugs
were found to have a lower incidence of the disease
(Notkola et al., 1998; Wolozin et al., 2000). Although
recent studies examining statin usage have produced
mixed conclusions, the epidemiological studies linking
high cholesterol levels with increased Aß production and
prevalence of AD have been supported by a number of
in vivo and in vitro studies. Thus, animals fed a high
cholesterol diet showed increased Aß accumulation and
increased BACE1 activity, whereas treatment with
cholesterol-lowering drugs resulted in lower Aß levels
(Fassbender et al., 2001). The differential localization of
APP and its secretases in cholesterol-rich lipid rafts is
thought to regulate the production of the neurotoxic Aß
peptide. Increasing evidence supports the hypothesis that
the amyloidogenic processing of APP occurs in
cholesterol-rich lipid rafts, while non-amyloidogenic
processing occurs mainly in other regions of the
membrane, and that altering cellular cholesterol levels
regulates the processing of APP through these two
pathways. Several studies have examined the
localization of APP, the α, ß-and γ-secretases in rafts,
mainly by exploiting the relative detergent insolubility
of such domains. Varying proportions of the presenilins
and the other components of the γ-secretase complex
(nicastrin, Aph-1 and Pen-2), along with γ-secretase
activity, as well as minor amounts of the γ-secretase
BACE1, are present in detergent-resistant rafts. In
addition, the activity of BACE1 is stimulated by some
lipid components of rafts, such as glycosphingolipids
and cholesterol (Kalvodova et al., 2005; Arigo et al.,
2008). Intriguingly, although the presence of APP in
detergent-resistant rafts is relatively minor (Lee et al.,
1998), once localized to the raft, the APP may be rapidly
cleaved by ß- and γ-secretases, thus contributing to Aß
generation.
In addition to its extracellular deposition, current
evidence indicates the processing and targeting of Ab to
intracellular sites, including mitochondria (Lin and Beal,
2006). Well before plaques are observed, intracellular
aggregates of Aß form early in mice overexpressing
APP, and these aggregates seem to congregate in
synaptic compartments and correlate with cognitive
impairment (Oddo et al., 2003). Moreover,
nonglycosylated full-length and C-terminally-truncated
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APP was associated with mitochondria in samples from
the brains of individuals with AD, but not with
mitochondria in samples from subjects without the
disease. Furthermore, within AD brain samples, levels of
mitochondrial APP were higher in more affected brain
areas and in subjects with more advanced disease (Devi
et al., 2006). Although it is currently unclear whether
APP processing and subsequent Aß generation occur
actually in mitochondria (Fallkeval et al., 2006;
Manczak et al., 2006), it has been shown that Aß can
target mitochondria to stimulate ROS generation,
contributing to Aß toxicity in neurons (Behl et al., 1994;
Casley et al., 2002; Lustbader et al., 2004). Considering
that mGSH functions as a survival factor which is
regulated by mitochondrial membrana dynamics, we
postulated that mGSH depletion due to mitochondrial
cholesterol accumulation may play a role in AD
pathology. Transgenic mice (NPC1, Tg-SREBP-2) with
increased brain cholesterol accumulation exhibited
enhanced mitochondrial cholesterol levels and mGSH
depletion and also exhibited a marked susceptibility to
Aß-induced neuronal cell death (Fernandez et al.,
manuscript in preparation). Conversely, lowering
mitochondrial cholesterol levels by statins or increasing
mGSH protected neurons against Aß-mediated cell
death. These findings may provide novel clues for
therapeutic benefits of statins in AD and suggest that
therapeutic combinations to boost neuronal mGSH
defense may slow down disease progression.
Concluding remarks
Life is incompatible in the absence of cholesterol,
but its accumulation contributes to life's threatening
diseases, as most prominently exemplified by the onset
of cardiovascular disorders. This duality reflects a
delicate balance between the complex roles of
cholesterol in the integration of signaling platforms
assembled at the plasma membrane through the
organization of specific domains and the modulation of
membrane's structure and biophysical properties. Less
recognized and studied has been the pool of
mitochondrial cholesterol in the regulation of
mitochondrial function and pathophysiology. Although
mitochondria constitute a minor destination in the
trafficking of cholesterol from the ER and plasma
membrane, mitochondrial cholesterol plays an important
physiological function in specialized tissues, providing
its steroid nucleus for bile acid and steroid hormone
synthesis. Current evidence, however, indicates that the
accumulation of cholesterol within mitochondrial
membranes emerges as a key factor in pathophysiology
by regulating both inner and outer membrane properties
and subsequent function of specific mitochondrial
proteins, including the permeabilizing activity of BAX
or the mitochondrial GSH carrier. Given the dependence
of the latter on appropriate membrane dynamics, the
loading of mitochondria in cholesterol impairs the
transport of cytosol GSH into mitochondria, resulting in
mitochondrial GSH depletion, which cripples the
mitochondrial antioxidant armamentarium and
contributes to steatohepatitis or the susceptibility of
neurons to amyloid toxicity. As our knowledge on the
regulation and trafficking of mitochondrial cholesterol
advances, this specific pool of cholesterol may emerge
as a novel therapeutic target in diseases.
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